Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant + Phesgo vs Phesgo in HER2+/ER+ Advanced Breast Cancer
NCT05296798Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2022
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Jul 2022; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05296798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296798.